Impact of Liraglutide on cardiac function and structure in Young adults with Type 2 Diabetes (Open label, randomised active comparator study)
Type 2 diabetes is becoming increasingly prevalent in younger adults under 50 years of age. Research has shown that type 2 diabetes in this group may take a more aggressive course compared to those who developed diabetes at a later age (>50 yrs). This includes increased risk of developing heart problems such as heart attack and reduced heart function. It is therefore important that younger adults with type 2 diabetes receive the best treatment.
The LYDIA study involves assigning patients randomly to one of the diabetes medications either Liragltuide or Sitagliptin for 6 months duration amd measuring heart (cardiac) function by state of the art imaging technique known as the cardiac MRI.
Although classed as newer medications, both drugs used in LYDIA study have been approved by National Institute for Health and Clinical Excellence (NICE) to be used for blood glucose control in people with type 2 diabetes.In both clinical trials and real life clinical practice, treatment with liraglutide results in weight loss in many patients while sitagliptin has neutral effect on weight in addition to improving diabetes control.
This study will compare which of these two diabetes medications has better effect on the heart (cardiac) function as measured by cardiac MRI.
If you have type 2 diabetes or know someone with type 2 diabetes who fits in the following criteria and would like to find out more, please use the contact detail below or see the patient information leaflet.
Poster Information about the LYDIA study for you to print and display. Download Document
Information about the study for patients Download Document